Eligible Populations
Cross-source consensus on Eligible Populations from 1 sources and 4 claims.
1 sources · 4 claims
Other
Other
Highlighted claims
- Eligible studies must include adults over 18 with MASLD, MASH, or equivalent steatotic liver disease diagnoses without additional non-metabolic chronic liver disease causes. — Safety and efficacy of pharmacological interventions for hepatic outcomes of metabolic dysfunction-associated steatotic liver disease: protocol for systematic review and network meta-analysis
- Studies involving non-metabolic liver disease, children, adolescents, animal models, or in vivo non-human work will be excluded. — Safety and efficacy of pharmacological interventions for hepatic outcomes of metabolic dysfunction-associated steatotic liver disease: protocol for systematic review and network meta-analysis
- Studies will not be excluded solely because they do not report cardiometabolic criteria, since much evidence predates current MASLD nomenclature. — Safety and efficacy of pharmacological interventions for hepatic outcomes of metabolic dysfunction-associated steatotic liver disease: protocol for systematic review and network meta-analysis
- Studies focused on advanced fibrosis, cirrhosis, diabetes, obesity, hypertension, or dyslipidaemia may be included. — Safety and efficacy of pharmacological interventions for hepatic outcomes of metabolic dysfunction-associated steatotic liver disease: protocol for systematic review and network meta-analysis